G82S polymorphism of receptor for advanced glycation end products gene and serum soluble RAGE levels in mild cognitive impairment and dementia of Alzheimer's type patients in Turkish population

J Clin Neurosci. 2019 Jan:59:197-201. doi: 10.1016/j.jocn.2018.10.072. Epub 2018 Oct 30.

Abstract

Alzheimer's disease (AD) is a chronic, neurodegenaration resulting in progressive cognitive decline leading to dementia. Mild cognitive impairment (MCI) is also a clinical definition of cognitive decline without functional impairment. Receptor for advanced glycation end products (RAGE) is one of the neuronal membrane receptors that binds amyloid beta peptide (Aβ) triggering Aβ-related pathologic signalling mechanisms. Soluble RAGE (sRAGE) is the soluble isoform of RAGE and it collects peripheral Aβ by acting as a sink, prevents both RAGE-AGE interaction and transfer of Aβ into brain. In this study, an association was investigated in Turkish cohorts of patients with dementia with Alzheimer's Type (DAT) and MCI patients by measuring serum sRAGE levels and by genotyping G82S polymorphism and comparing them to healthy control (HC) subjects. Although the serum sRAGE levels showed a decreasing manner among the groups, these differences were not statistically significant (p = 0.2). This is the first study for Turkish population.

Keywords: AD; Mild cognitive impairment; Polymorphism; RAGE gene (AGER); sRAGE.

MeSH terms

  • Aged
  • Alzheimer Disease / blood*
  • Alzheimer Disease / genetics*
  • Amyloid beta-Peptides / metabolism
  • Cognitive Dysfunction / etiology
  • Female
  • Genotype
  • Humans
  • Male
  • Polymorphism, Genetic
  • Receptor for Advanced Glycation End Products / genetics*
  • Receptor for Advanced Glycation End Products / metabolism*

Substances

  • Amyloid beta-Peptides
  • Receptor for Advanced Glycation End Products